DMK PHARMACEUTICALS CORPORATION: 10-Q filed 2023-05-15

Name: DMK PHARMACEUTICALS CORPORATION: 10-Q filed 2023-05-15
Creator: DMK PHARMACEUTICALS CORPORATION

What DMK PHARMACEUTICALS CORPORATION reported in its quarterly report filed 2023-05-15 (fiscal Q1 2023): 38 published measures, 77 facts as tagged in accession 0001387131-23-006540.

This filing

Form: 10-Q (quarterly report)
Filed: 2023-05-15
Fiscal period: fiscal Q1 2023
Accession: 0001387131-23-006540 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All DMK PHARMACEUTICALS CORPORATION filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

Period	Value	Unit	Days
At 2023-03-31	9,076,095	USD
At 2022-12-31	10,930,840	USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

Period	Value	Unit	Days
At 2023-03-31	18,600,473	USD
At 2022-12-31	11,581,605	USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

Period	Value	Unit
At 2023-03-31	-9,681,681	USD
At 2022-12-31	-808,068	USD
At 2022-03-31	15,900,281	USD
At 2021-12-31	25,882,778	USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

Period	Value	Unit
At 2023-03-31	3,099,843	USD
At 2022-12-31	1,081,364	USD
At 2022-03-31	17,767,735	USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

Period	Value	Unit	Days
2023-01-01 to 2023-03-31	-8,942,907	USD	90
2022-01-01 to 2022-03-31	-10,354,615	USD	90

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

Period	Value	Unit	Days
2023-01-01 to 2023-03-31	-1,547,538	USD	90
2022-01-01 to 2022-03-31	-6,985,736	USD	90

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

Period	Value	Unit	Days
2022-01-01 to 2022-03-31	26,928	USD	90

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

Period	Value	Unit	Days
2023-01-01 to 2023-03-31	1,453,000	USD	90
2022-01-01 to 2022-03-31	1,154,514	USD	90

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

Period	Value	Unit	Days
2023-01-01 to 2023-03-31	2,724,250	USD	90

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

Period	Value	Unit	Days
2023-01-01 to 2023-03-31	841,778	USD	90
2022-01-01 to 2022-03-31	1,532,712	USD	90

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

Period	Value	Unit	Days
At 2023-03-31	-313,506,993	USD
At 2022-12-31	-304,564,086	USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

Period	Value	Unit	Days
2023-01-01 to 2023-03-31	152,916,598	shares	90
2022-01-01 to 2022-03-31	149,617,429	shares	90

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

Period	Value	Unit	Days
2023-01-01 to 2023-03-31	152,916,598	shares	90
2022-01-01 to 2022-03-31	149,617,429	shares	90

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

Period	Value	Unit	Days
2023-01-01 to 2023-03-31	-0.06	USD/shares	90
2022-01-01 to 2022-03-31	-0.07	USD/shares	90

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

Period	Value	Unit	Days
2023-01-01 to 2023-03-31	-0.06	USD/shares	90
2022-01-01 to 2022-03-31	-0.07	USD/shares	90

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

Period	Value	Unit	Days
At 2023-03-31	1,244,669	USD
At 2022-12-31	1,288,894	USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

Period	Value	Unit	Days
2023-01-01 to 2023-03-31	69,294	USD	90
2022-01-01 to 2022-03-31	372,118	USD	90

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

Period	Value	Unit	Days
2023-01-01 to 2023-03-31	-6,427,681	USD	90
2022-01-01 to 2022-03-31	-7,913,289	USD	90

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

Period	Value	Unit	Days
At 2023-03-31	7,547,030	USD
At 2022-12-31	9,272,150	USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

Period	Value	Unit	Days
At 2023-03-31	12,948,525	USD
At 2022-12-31	11,395,866	USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

Period	Value	Unit	Days
At 2023-03-31	9,780,979	USD
At 2022-12-31	7,937,493	USD

Net inventory

Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.

Period	Value	Unit	Days
At 2023-03-31	664,358	USD
At 2022-12-31	1,238,778	USD

Gross profit

Revenue less the costs directly attributed to the goods or services sold. It precedes other operating expenses and is not net income.

Period	Value	Unit	Days
2023-01-01 to 2023-03-31	-335,066	USD	90
2022-01-01 to 2022-03-31	-309,068	USD	90

Selling, general and administrative expense

Selling and general administrative costs reported under this concept. It is an expense category, not a substitute for total operating expenses.

Period	Value	Unit	Days
2023-01-01 to 2023-03-31	4,782,086	USD	90
2022-01-01 to 2022-03-31	3,382,696	USD	90

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

Period	Value	Unit	Days
2023-01-01 to 2023-03-31	1,310,529	USD	90
2022-01-01 to 2022-03-31	4,221,525	USD	90

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

Period	Value	Unit	Days
At 2023-03-31	166,483,265	shares
At 2022-12-31	149,983,265	shares

Operating lease right-of-use asset

Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.

Period	Value	Unit	Days
At 2023-03-31	232,222	USD
At 2022-12-31	317,622	USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

Period	Value	Unit	Days
At 2023-03-31	4,774,537	USD
At 2022-12-31	4,665,067	USD

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

Period	Value	Unit	Days
At 2023-03-31	52,174	USD
At 2022-12-31	52,174	USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

Period	Value	Unit	Days
At 2023-03-31	1,829,554	USD
At 2022-12-31	1,510,053	USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

Period	Value	Unit	Days
At 2023-03-31	750,272	USD
At 2022-12-31	1,884,015	USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

Period	Value	Unit	Days
2023-01-01 to 2023-03-31	-9,014,608	USD	90
2022-01-01 to 2022-03-31	-10,189,754	USD	90

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

Period	Value	Unit	Days
2023-01-01 to 2023-03-31	109,000	USD	90
2022-01-01 to 2022-03-31	344,000	USD	90

Other nonoperating income or expense

Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.

Period	Value	Unit	Days
2023-01-01 to 2023-03-31	-113,034	USD	90
2022-01-01 to 2022-03-31	-440,000	USD	90

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

Period	Value	Unit	Days
2023-01-01 to 2023-03-31	-2,586,927	USD	90
2022-01-01 to 2022-03-31	-2,276,465	USD	90

Change in accounts receivable

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

Period	Value	Unit	Days
2023-01-01 to 2023-03-31	-1,054,058	USD	90
2022-01-01 to 2022-03-31	784,524	USD	90

Change in inventories

The cash flow adjustment for the change in inventories during the period. A positive value under this concept means inventory grew and reduced operating cash flow.

Period	Value	Unit	Days
2023-01-01 to 2023-03-31	-574,420	USD	90
2022-01-01 to 2022-03-31	-394,030	USD	90

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

Period	Value	Unit	Days
2023-01-01 to 2023-03-31	1,778,241	USD	90
2022-01-01 to 2022-03-31	1,171,894	USD	90

Inspect the source

Entity: DMK PHARMACEUTICALS CORPORATION / CIK 0000887247
Captured: 2026-09-22 19:32 UTC
SEC response SHA-256: cc88d438258619b3d6acde0c3ef806d208e463a48f69c1a0310fac7d087cb187

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0000887247.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))